Novo Nordisk Says Global Payer Pressure Limits Price Rises
This article was originally published in Scrip
Executive Summary
Novo Nordisk A/S says the pricing environment for its drugs is getting more difficult globally, not least in the US, but the Danish diabetes fighter hopes the launch of its once-daily, next-generation basal insulin analogue Tresiba (insulin degludec) will help it expand market share there.